Currently, there are no targeted therapies or predictive biomarkers in routine clinical use for SCLC patients, although several are currently under investigation including DLL3 protein expression for the use of DLL3-directed CAR-T cell 3 or bispecific-antibody targeting 4,5 as well as SLFN11 expression to select patients for PARP-inhibitor treatments 6. The gene discussed is DLL3; the disease is small cell lung carcinoma.